Skip to main content
. 2018 May-Jun;15(5-6):22–29.

FIGURE 2.

FIGURE 2.

Percentage of participants categorized as exhibiting remission* and nonremission* based on SDS total score in (top graph) Study 1 and (bottom graph) Study 2, full analysis set

*Remission (no or minimal functional disability) was defined as SDS total score ≤6.

†Nonremission (some level of functional disability) was defined as SDS total score >6.

LDX: lisdexamfetamine dimesylate; PBO: placebo; SDS: Sheehan Disability Scale